Outlook Therapeutics (OTLK) Income from Continuing Operations: 2015-2024
Historic Income from Continuing Operations for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$75.4 million.
- Outlook Therapeutics' Income from Continuing Operations rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$38.3 million, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- As of FY2024, Outlook Therapeutics' Income from Continuing Operations stood at -$75.4 million, which was down 27.78% from -$59.0 million recorded in FY2023.
- In the past 5 years, Outlook Therapeutics' Income from Continuing Operations ranged from a high of -$35.2 million in FY2020 and a low of -$75.4 million during FY2024.
- Over the past 3 years, Outlook Therapeutics' median Income from Continuing Operations value was -$66.1 million (recorded in 2022), while the average stood at -$66.8 million.
- Per our database at Business Quant, Outlook Therapeutics' Income from Continuing Operations plummeted by 50.86% in 2021 and then rose by 10.70% in 2023.
- Over the past 5 years, Outlook Therapeutics' Income from Continuing Operations (Yearly) stood at -$35.2 million in 2020, then tumbled by 50.86% to -$53.2 million in 2021, then decreased by 24.24% to -$66.1 million in 2022, then grew by 10.70% to -$59.0 million in 2023, then fell by 27.78% to -$75.4 million in 2024.